Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Rocket Pharmaceuticals, Inc. Warrant (RCKTW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: RCKTW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -89.92% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 23146 | Beta - | 52 Weeks Range 0.02 - 0.23 | Updated Date 02/26/2025 |
52 Weeks Range 0.02 - 0.23 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Rocket Pharmaceuticals, Inc. Warrant
Company Overview
History and Background
Rocket Pharmaceuticals is a clinical-stage biotechnology company focused on developing gene therapies for rare pediatric diseases. While the warrant itself doesn't have a founding year, it's related to Rocket Pharmaceuticals' financing events. Founded in 2015, Rocket has focused on developing lentiviral and adeno-associated viral (AAV) based gene therapies. Significant milestones include IND approvals for multiple programs and clinical trial initiations.
Core Business Areas
- Gene Therapy Development: Development of gene therapies for rare pediatric diseases. Focus on ex-vivo lentiviral vector (LVV) and in-vivo adeno-associated viral vector (AAV) based therapies.
Leadership and Structure
The leadership team consists of experienced executives in the biotechnology and pharmaceutical industries. The organizational structure includes research and development, clinical operations, regulatory affairs, and commercial functions.
Top Products and Market Share
Key Offerings
- Market Share (%): NA
- RP-L102 (Fanconi Anemia Group A): An ex-vivo LVV gene therapy for Fanconi Anemia Group A (FA-A). Currently in clinical trials. Competition includes supportive care and bone marrow transplantation.
- Market Share (%): NA
- RP-L201 (Leukocyte Adhesion Deficiency-I): An ex-vivo LVV gene therapy for Leukocyte Adhesion Deficiency-I (LAD-I). Currently in clinical trials. Competition includes supportive care and bone marrow transplantation.
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, driven by advancements in vector technology and increasing clinical success. The market is competitive with numerous companies developing therapies for various rare diseases.
Positioning
Rocket Pharmaceuticals is positioned as a leader in developing gene therapies for rare pediatric diseases. Their competitive advantage lies in their experienced team and focus on clinically validated targets.
Total Addressable Market (TAM)
The total addressable market for gene therapies is estimated to be in the tens of billions of dollars. Rocket Pharmaceuticals is positioned to capture a portion of this TAM by developing therapies for rare diseases with high unmet medical needs.
Upturn SWOT Analysis
Strengths
- Strong pipeline of gene therapy candidates
- Experienced management team
- Focus on rare pediatric diseases with high unmet needs
- Established manufacturing capabilities
Weaknesses
- Clinical trial risks and uncertainties
- Regulatory hurdles
- High manufacturing costs
- Reliance on successful clinical trial outcomes
Opportunities
- Expansion of pipeline into new rare diseases
- Partnerships with larger pharmaceutical companies
- Commercialization of approved gene therapies
- Advancements in gene therapy technology
Threats
- Competition from other gene therapy companies
- Adverse clinical trial results
- Changes in regulatory landscape
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- BLUE
- CRSP
- EDIT
- BEAM
Competitive Landscape
Rocket Pharmaceuticals faces competition from other gene therapy companies, but their focus on rare pediatric diseases and established manufacturing capabilities provide a competitive advantage.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Rocket Pharmaceuticals' growth is primarily driven by advancements in its clinical pipeline.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary but generally project significant revenue growth upon commercialization of gene therapies.
Recent Initiatives: Recent initiatives include progressing clinical trials, expanding manufacturing capabilities, and exploring partnerships.
Summary
Rocket Pharmaceuticals, a company specializing in rare pediatric disease gene therapies, displays potential but is subject to high risk and uncertainty typical of clinical-stage biotechs. Its pipeline and experienced team are working well but successful clinical trial results are critical. Competition and regulatory changes are concerns. The company does not own a material amount of the market share.
Similar Companies
BEAM
Beam Therapeutics Inc
BEAM
Beam Therapeutics Inc
BLUE
Bluebird bio Inc
BLUE
Bluebird bio Inc
CRSP
Crispr Therapeutics AG
CRSP
Crispr Therapeutics AG
EDIT
Editas Medicine Inc
EDIT
Editas Medicine Inc
Sources and Disclaimers
Data Sources:
- Rocket Pharmaceuticals Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rocket Pharmaceuticals, Inc. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-02-27 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 240 | Website |
Full time employees 240 | Website | ||
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. The company is headquartered in Cranbury, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.